Johnson & Johnson Restructuring Device Business, Cutting Up to 3000 Jobs
This morning Johnson & Johnson announced that it will be restructuring its medical device business in an effort to save between $800 million and $1 billion by 2018. As a result, the company will eliminate 4–6% of jobs (approximately 3000) globally over the next two years. Johnson & Johnson will reportedly restructure into the following areas:
- Cardiovascular
- Diabetes
- Diagnostics
- Orthopedics
- Surgery
- Vision Care
“As a market leader, we are committed to leveraging our breadth and scale to shape the future of the medical device industry, for the benefit of those we serve,” said Gary Pruden, Worldwide Chairman, Johnson & Johnson Medical Devices, in a company press release. “The bold steps we are taking today are to evolve our offerings, structure and footprint and increase our investment in innovation. These actions recognize the changing needs of the global medical device market and will deliver more value to customers, increasing our competitive advantage and driving growth and profitability for our business.”
According to The Wall Street Journal, the restructuring mainly hits the orthopedics, surgery and cardiovascular segments; its diabetes, vision care, and consumer device segments won’t be affected.
Related Articles
-
The $16.6 billion acquisition will bring Abiomed’s breakthough Impella heart pumps into the Johnson & Johnson MedTech portfolio.
-
It is more important than ever for medical manufacturers to prepare for business interruption due to unexpected damage or natural disasters. From building a recovery team to securing proper insurance, there are many steps device manufacturers can take to recover…
-
The UK MHRA has published “Software and Artificial Intelligence as a Medical Device.” The guidance document assembles previous guidances and regulatory requirements for SaMD and AIaMD devices seeking commercialization in the UK market.
-
“Addressing unmet needs across pediatric populations is critical to advancing children’s health, and we are delighted to once again work with pioneering companies that seek to bridge this care gap."
